Physician profile
Joseph Abboud
NPI 1710168901
$2,077.04
in general payments reported to CMS, 2019-2025
17 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $111 · 2021: $303 · 2022: $230 · 2023: $142 · 2024: $557 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.70 |
| Education | $218.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $367.94 | 2023-2024 | Watchman, Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $274.09 | 2022-2025 | Opsumit, Uptravi |
| Amgen INC. | $224.92 | 2019-2021 | |
| Trice Medical, INC. | $200.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $181.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $171.15 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $150.53 | 2021-2023 | |
| Novo Nordisk INC | $112.17 | 2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic Vascular, INC. | $91.07 | 2019 | |
| Zimmer Biomet Holdings, INC. | $89.81 | 2022-2025 | Juggerknotless Soft Anchor |
| E.R. Squibb & Sons, L.L.C. | $45.01 | 2019-2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $39.84 | 2024 | |
| Astellas Pharma US INC | $33.92 | 2024 | Cresemba |
| Vifor Pharma, INC. | $29.08 | 2024 | Veltassa |
| Medtronic, INC. | $27.22 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $23.90 | 2023 | Inpefa |
| Amarin Pharma, INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.